The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Recursion Pharmaceuticals Inc (NASDAQ: RXRX) was $6.64 for the day, up 3.75% from the previous closing price of $6.40. In other words, the price has increased by $3.75 from its previous closing price. On the day, 3.87 million shares were traded. RXRX stock price reached its highest trading level at $6.69 during the session, while it also had its lowest trading level at $6.22.
Ratios:
Our analysis of RXRX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.07 and its Current Ratio is at 6.07. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.13.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on May 22, 2023, initiated with a Equal-Weight rating and assigned the stock a target price of $8.
On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.
On September 16, 2022, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $20.KeyBanc Capital Markets initiated its Overweight rating on September 16, 2022, with a $20 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 29 ’24 when Borgeson Blake sold 11,447 shares for $6.72 per share. The transaction valued at 76,926 led to the insider holds 7,077,560 shares of the business.
Borgeson Blake bought 11,447 shares of RXRX for $76,926 on Oct 29 ’24. On Oct 24 ’24, another insider, Marriott Tina, who serves as the President and COO of the company, sold 6,000 shares for $6.31 each. As a result, the insider received 37,855 and left with 521,138 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 1935745920 and an Enterprise Value of 1481164416. For the stock, the TTM Price-to-Sale (P/S) ratio is 39.47 while its Price-to-Book (P/B) ratio in mrq is 3.19. Its current Enterprise Value per Revenue stands at 29.841 whereas that against EBITDA is -4.059.
Stock Price History:
Over the past 52 weeks, RXRX has reached a high of $15.74, while it has fallen to a 52-week low of $5.03. The 50-Day Moving Average of the stock is 0.28%, while the 200-Day Moving Average is calculated to be -22.14%.
Shares Statistics:
RXRX traded an average of 4.85M shares per day over the past three months and 3677450 shares per day over the past ten days. A total of 291.36M shares are outstanding, with a floating share count of 226.84M. Insiders hold about 22.15% of the company’s shares, while institutions hold 77.83% stake in the company. Shares short for RXRX as of 1728950400 were 59436441 with a Short Ratio of 12.25, compared to 1726185600 on 59162424. Therefore, it implies a Short% of Shares Outstanding of 59436441 and a Short% of Float of 22.97.
